Global Targeted Alpha-particle Therapy Supply, Demand and Key Producers, 2026-2032
The global Targeted Alpha-particle Therapy market size is expected to reach $ 3932 million by 2032, rising at a market growth of 18.2% CAGR during the forecast period (2026-2032).
Targeted Alpha-particle Therapy (TAT) is a novel radiopharmaceutical treatment technique that utilizes alpha-emitting radionuclides conjugated with targeting molecules to precisely kill tumor cells. The fundamental principle involves delivering alpha-emitting radionuclides—which possess potent cell-killing capabilities (such as Radium-223, Actinium-225, Bismuth-213, Lead-212, and Astatine-211)—to tumor tissues via antibodies, peptides, small-molecule ligands, or other biological targeting vectors. These radionuclides release high-energy alpha particles in the vicinity of cancer cells; the resulting radiation, characterized by a very short range and high Linear Energy Transfer (LET), directly disrupts the double-strand structure of cancer cell DNA, thereby inducing apoptosis or irreversible damage to the tumor cells. Compared to traditional beta-particle radiotherapy, alpha particles possess high energy and a short range of action (typically only tens of micrometers, equivalent to the diameter of a few cells), allowing for the destruction of tumor cells while minimizing radiation damage to surrounding healthy tissues.
TAT represents a significant development in the fields of precision nuclear medicine and radiopharmaceuticals; its core components include alpha-emitting radionuclides, targeting delivery molecules, and drug conjugation technology platforms. Specifically, the alpha radionuclide determines the therapeutic energy and half-life characteristics; the targeting molecule dictates the drug's ability to recognize tumor cells; and chelating agents and conjugation technologies influence radionuclide stability and in vivo distribution. Currently, this technology is primarily applied to the treatment of refractory cancers, including prostate cancer, neuroendocrine tumors, leukemia, ovarian cancer, and pancreatic cancer. Notably, Radium-223 dichloride is already used to treat bone-metastatic prostate cancer, while targeted radiopharmaceuticals based on radionuclides such as Actinium-225 and Lead-212 are becoming a focal point of clinical research.
From an industry chain perspective, the upstream sector primarily encompasses alpha radionuclide production, isotope separation and purification, nuclear reactor or accelerator facilities, and the development of chelating agents and targeting vectors. The midstream sector consists mainly of radiopharmaceutical R&D companies responsible for radionuclide labeling, drug preparation, quality control, and clinical development. The downstream sector includes hospital nuclear medicine departments, oncology treatment centers, and clinical application for patients. Due to challenges such as difficult production, complex supply chains, short half-lives, and stringent requirements for transport and storage, the number of enterprises and institutions worldwide capable of supplying alpha-emitting radionuclides at scale remains limited.
Looking ahead, the development of Targeted Alpha-particle Therapy will be driven by factors such as the growing demand for precision oncology, the accelerated R&D of innovative nuclear medicine drugs, and enhanced supply capabilities for radioactive isotopes. With continuous breakthroughs in production technologies for novel therapeutic radionuclides—such as Actinium-225 and Lead-212—alongside advancements in AI-assisted drug design, companion diagnostics, and personalized dosimetry, targeted alpha therapy is poised to emerge as a major cancer treatment modality following chemotherapy, immunotherapy, and beta-emitter therapy. This evolution will propel the radiopharmaceutical industry toward greater precision, efficiency, and personalization.
The core drivers of the Targeted Alpha-particle Therapy industry's growth stem from the rising global demand for cancer treatment and the deepening adoption of precision oncology concepts. As the global incidence of cancer rises—along with the number of patients suffering from advanced solid tumors, metastatic cancer, and refractory malignancies—traditional chemotherapy, immunotherapy, and beta-radionuclide therapies have shown limitations in efficacy or tolerability for certain patient populations. By leveraging the high linear energy transfer (LET) characteristics of alpha particles, targeted alpha-particle therapy induces DNA double-strand breaks in tumor cells over extremely short distances, achieving highly efficient cell killing while minimizing radiation exposure to surrounding healthy tissues; consequently, it demonstrates significant clinical value in treating prostate cancer, neuroendocrine tumors, hematologic malignancies, and various solid tumors.
Advancements in radiopharmaceutical R&D technologies and improved supply capabilities for key alpha-emitting radionuclides are propelling industry growth. In recent years, therapeutic alpha-emitters such as Actinium-225, Lead-212, Bismuth-213, and Astatine-211 have garnered widespread attention; continuous optimization of radionuclide production, separation and purification, radiolabeling, and chelator technologies has enhanced the feasibility of developing alpha-emitter-based drugs. Simultaneously, the development of targeting agents—including antibodies, peptides, and small-molecule ligands—along with novel delivery platforms, enables alpha-emitters to target tumor cells with greater precision and improves control over drug distribution within the body. With the maturation of nuclear medicine infrastructure and an increasing number of clinical trials, targeted alpha-particle therapy is transitioning from early-stage scientific research toward commercial application.
Furthermore, targeted alpha-particle therapy is poised to expand into a broader range of cancer types and evolve toward combination therapies and intelligent, data-driven approaches. Future R&D will shift from developing drugs for single indications to creating radiopharmaceutical platforms that cover a wider array of cancers, such as prostate, breast, pancreatic, and ovarian cancers, as well as gliomas. Additionally, alpha-emitter therapy is expected to integrate with immunotherapy, targeted therapy, and genetic testing technologies, enabling highly personalized treatment plans through patient screening based on molecular biomarkers and precision dosimetry. Developments in AI-assisted drug screening, image-guided dose assessment, and companion diagnostics will further enhance therapeutic outcomes and the efficiency of clinical application.
This report is a detailed and comprehensive analysis of the world market for Targeted Alpha-particle Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Alpha-particle Therapy that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted Alpha-particle Therapy market
2. What is the demand of the global Targeted Alpha-particle Therapy market?
3. What is the year over year growth of the global Targeted Alpha-particle Therapy market?
4. What is the total value of the global Targeted Alpha-particle Therapy market?
5. Who are the Major Players in the global Targeted Alpha-particle Therapy market?
6. What are the growth factors driving the market demand?
Targeted Alpha-particle Therapy (TAT) is a novel radiopharmaceutical treatment technique that utilizes alpha-emitting radionuclides conjugated with targeting molecules to precisely kill tumor cells. The fundamental principle involves delivering alpha-emitting radionuclides—which possess potent cell-killing capabilities (such as Radium-223, Actinium-225, Bismuth-213, Lead-212, and Astatine-211)—to tumor tissues via antibodies, peptides, small-molecule ligands, or other biological targeting vectors. These radionuclides release high-energy alpha particles in the vicinity of cancer cells; the resulting radiation, characterized by a very short range and high Linear Energy Transfer (LET), directly disrupts the double-strand structure of cancer cell DNA, thereby inducing apoptosis or irreversible damage to the tumor cells. Compared to traditional beta-particle radiotherapy, alpha particles possess high energy and a short range of action (typically only tens of micrometers, equivalent to the diameter of a few cells), allowing for the destruction of tumor cells while minimizing radiation damage to surrounding healthy tissues.
TAT represents a significant development in the fields of precision nuclear medicine and radiopharmaceuticals; its core components include alpha-emitting radionuclides, targeting delivery molecules, and drug conjugation technology platforms. Specifically, the alpha radionuclide determines the therapeutic energy and half-life characteristics; the targeting molecule dictates the drug's ability to recognize tumor cells; and chelating agents and conjugation technologies influence radionuclide stability and in vivo distribution. Currently, this technology is primarily applied to the treatment of refractory cancers, including prostate cancer, neuroendocrine tumors, leukemia, ovarian cancer, and pancreatic cancer. Notably, Radium-223 dichloride is already used to treat bone-metastatic prostate cancer, while targeted radiopharmaceuticals based on radionuclides such as Actinium-225 and Lead-212 are becoming a focal point of clinical research.
From an industry chain perspective, the upstream sector primarily encompasses alpha radionuclide production, isotope separation and purification, nuclear reactor or accelerator facilities, and the development of chelating agents and targeting vectors. The midstream sector consists mainly of radiopharmaceutical R&D companies responsible for radionuclide labeling, drug preparation, quality control, and clinical development. The downstream sector includes hospital nuclear medicine departments, oncology treatment centers, and clinical application for patients. Due to challenges such as difficult production, complex supply chains, short half-lives, and stringent requirements for transport and storage, the number of enterprises and institutions worldwide capable of supplying alpha-emitting radionuclides at scale remains limited.
Looking ahead, the development of Targeted Alpha-particle Therapy will be driven by factors such as the growing demand for precision oncology, the accelerated R&D of innovative nuclear medicine drugs, and enhanced supply capabilities for radioactive isotopes. With continuous breakthroughs in production technologies for novel therapeutic radionuclides—such as Actinium-225 and Lead-212—alongside advancements in AI-assisted drug design, companion diagnostics, and personalized dosimetry, targeted alpha therapy is poised to emerge as a major cancer treatment modality following chemotherapy, immunotherapy, and beta-emitter therapy. This evolution will propel the radiopharmaceutical industry toward greater precision, efficiency, and personalization.
The core drivers of the Targeted Alpha-particle Therapy industry's growth stem from the rising global demand for cancer treatment and the deepening adoption of precision oncology concepts. As the global incidence of cancer rises—along with the number of patients suffering from advanced solid tumors, metastatic cancer, and refractory malignancies—traditional chemotherapy, immunotherapy, and beta-radionuclide therapies have shown limitations in efficacy or tolerability for certain patient populations. By leveraging the high linear energy transfer (LET) characteristics of alpha particles, targeted alpha-particle therapy induces DNA double-strand breaks in tumor cells over extremely short distances, achieving highly efficient cell killing while minimizing radiation exposure to surrounding healthy tissues; consequently, it demonstrates significant clinical value in treating prostate cancer, neuroendocrine tumors, hematologic malignancies, and various solid tumors.
Advancements in radiopharmaceutical R&D technologies and improved supply capabilities for key alpha-emitting radionuclides are propelling industry growth. In recent years, therapeutic alpha-emitters such as Actinium-225, Lead-212, Bismuth-213, and Astatine-211 have garnered widespread attention; continuous optimization of radionuclide production, separation and purification, radiolabeling, and chelator technologies has enhanced the feasibility of developing alpha-emitter-based drugs. Simultaneously, the development of targeting agents—including antibodies, peptides, and small-molecule ligands—along with novel delivery platforms, enables alpha-emitters to target tumor cells with greater precision and improves control over drug distribution within the body. With the maturation of nuclear medicine infrastructure and an increasing number of clinical trials, targeted alpha-particle therapy is transitioning from early-stage scientific research toward commercial application.
Furthermore, targeted alpha-particle therapy is poised to expand into a broader range of cancer types and evolve toward combination therapies and intelligent, data-driven approaches. Future R&D will shift from developing drugs for single indications to creating radiopharmaceutical platforms that cover a wider array of cancers, such as prostate, breast, pancreatic, and ovarian cancers, as well as gliomas. Additionally, alpha-emitter therapy is expected to integrate with immunotherapy, targeted therapy, and genetic testing technologies, enabling highly personalized treatment plans through patient screening based on molecular biomarkers and precision dosimetry. Developments in AI-assisted drug screening, image-guided dose assessment, and companion diagnostics will further enhance therapeutic outcomes and the efficiency of clinical application.
Report Scope
This report studies the global Targeted Alpha-particle Therapy demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Targeted Alpha-particle Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Targeted Alpha-particle Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Targeted Alpha-particle Therapy total market, 2021-2032, (USD Million)
- Global Targeted Alpha-particle Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Targeted Alpha-particle Therapy total market, key domestic companies, and share, (USD Million)
- Global Targeted Alpha-particle Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Targeted Alpha-particle Therapy total market by Type, CAGR, 2021-2032, (USD Million)
- Global Targeted Alpha-particle Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Targeted Alpha-particle Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Targeted Alpha-particle Therapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Global Targeted Alpha-particle Therapy Market, Segmentation by Type:
- Actinium-225
- Astatine-211
- Lead-212
- Bismuth-213
- Others
Global Targeted Alpha-particle Therapy Market, Segmentation by Targeted Carriers:
- Antibody-based ? Therapy
- Peptide Receptor Radionuclide Therapy
- Small Molecule ? Therapy
- Nano-carrier ? Therapy
- Cell-based ? Therapy
Global Targeted Alpha-particle Therapy Market, Segmentation by Therapeutic Target:
- PSMA-targeted Alpha Therapy
- SSTR-targeted Alpha Therapy
- CD33/CD45-targeted Alpha Therapy
- HER2-targeted Alpha Therapy
- EGFR-targeted Alpha Therapy
- Others
Global Targeted Alpha-particle Therapy Market, Segmentation by Drug Delivery Method:
- Systemic Administration
- Local Administration
- Radioimmunotherapy
- Combination Therapy Alpha Drugs
Global Targeted Alpha-particle Therapy Market, Segmentation by Application:
- Immunotherapy
- Peritoneal Carcinomas
- Bone Metastases
- Leukaemia
- Melanomas
- Solid Tumours
Companies Profiled:
- Bayer
- Orano Med
- Oncoinvent AS
- Perspective Therapeutics
- Ablaze Pharma
- ARTBIO
- Fusion Pharmaceuticals(AstraZeneca)
- AlphaGen Therapeutics
Key Questions Answered
1. How big is the global Targeted Alpha-particle Therapy market?2. What is the demand of the global Targeted Alpha-particle Therapy market?
3. What is the year over year growth of the global Targeted Alpha-particle Therapy market?
4. What is the total value of the global Targeted Alpha-particle Therapy market?
5. Who are the Major Players in the global Targeted Alpha-particle Therapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Targeted Alpha-particle Therapy Introduction
1.2 World Targeted Alpha-particle Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Targeted Alpha-particle Therapy Total Market by Region (by Headquarter Location)
1.3.1 World Targeted Alpha-particle Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.3 China Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.4 Europe Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.5 Japan Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.8 India Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Targeted Alpha-particle Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.2 World Targeted Alpha-particle Therapy Consumption Value by Region
2.2.1 World Targeted Alpha-particle Therapy Consumption Value by Region (2021-2026)
2.2.2 World Targeted Alpha-particle Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.4 China Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.5 Europe Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.6 Japan Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.7 South Korea Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.8 ASEAN Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.9 India Targeted Alpha-particle Therapy Consumption Value (2021-2032)
3 WORLD TARGETED ALPHA-PARTICLE THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Targeted Alpha-particle Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Targeted Alpha-particle Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Targeted Alpha-particle Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for Targeted Alpha-particle Therapy in 2025
3.3 Targeted Alpha-particle Therapy Company Evaluation Quadrant
3.4 Targeted Alpha-particle Therapy Market: Overall Company Footprint Analysis
3.4.1 Targeted Alpha-particle Therapy Market: Region Footprint
3.4.2 Targeted Alpha-particle Therapy Market: Company Product Type Footprint
3.4.3 Targeted Alpha-particle Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Targeted Alpha-particle Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Targeted Alpha-particle Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Targeted Alpha-particle Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Targeted Alpha-particle Therapy Consumption Value Comparison
4.2.1 United States VS China: Targeted Alpha-particle Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Targeted Alpha-particle Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Targeted Alpha-particle Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based Targeted Alpha-particle Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026)
4.4 China Based Companies Targeted Alpha-particle Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based Targeted Alpha-particle Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026)
4.5 Rest of World Based Targeted Alpha-particle Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Targeted Alpha-particle Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Targeted Alpha-particle Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Targeted Alpha-particle Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Actinium-225
5.2.2 Astatine-211
5.2.3 Lead-212
5.2.4 Bismuth-213
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
5.3.2 World Targeted Alpha-particle Therapy Market Size by Type (2027-2032)
5.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY TARGETED CARRIERS
6.1 World Targeted Alpha-particle Therapy Market Size Overview by Targeted Carriers: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Targeted Carriers
6.2.1 Antibody-based ? Therapy
6.2.2 Peptide Receptor Radionuclide Therapy
6.2.3 Small Molecule ? Therapy
6.2.4 Nano-carrier ? Therapy
6.2.5 Cell-based ? Therapy
6.3 Market Segment by Targeted Carriers
6.3.1 World Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2021-2026)
6.3.2 World Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2027-2032)
6.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2027-2032)
7 MARKET ANALYSIS BY THERAPEUTIC TARGET
7.1 World Targeted Alpha-particle Therapy Market Size Overview by Therapeutic Target: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Therapeutic Target
7.2.1 PSMA-targeted Alpha Therapy
7.2.2 SSTR-targeted Alpha Therapy
7.2.3 CD33/CD45-targeted Alpha Therapy
7.2.4 HER2-targeted Alpha Therapy
7.2.5 EGFR-targeted Alpha Therapy
7.2.6 Others
7.3 Market Segment by Therapeutic Target
7.3.1 World Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2021-2026)
7.3.2 World Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2027-2032)
7.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2027-2032)
8 MARKET ANALYSIS BY DRUG DELIVERY METHOD
8.1 World Targeted Alpha-particle Therapy Market Size Overview by Drug Delivery Method: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Drug Delivery Method
8.2.1 Systemic Administration
8.2.2 Local Administration
8.2.3 Radioimmunotherapy
8.2.4 Combination Therapy Alpha Drugs
8.3 Market Segment by Drug Delivery Method
8.3.1 World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2021-2026)
8.3.2 World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2027-2032)
8.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Targeted Alpha-particle Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Immunotherapy
9.2.2 Peritoneal Carcinomas
9.2.3 Bone Metastases
9.2.4 Leukaemia
9.2.5 Melanomas
9.2.6 Solid Tumours
9.3 Market Segment by Application
9.3.1 World Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
9.3.2 World Targeted Alpha-particle Therapy Market Size by Application (2027-2032)
9.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Bayer
10.1.1 Bayer Details
10.1.2 Bayer Major Business
10.1.3 Bayer Targeted Alpha-particle Therapy Product and Services
10.1.4 Bayer Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Bayer Recent Developments/Updates
10.1.6 Bayer Competitive Strengths & Weaknesses
10.2 Orano Med
10.2.1 Orano Med Details
10.2.2 Orano Med Major Business
10.2.3 Orano Med Targeted Alpha-particle Therapy Product and Services
10.2.4 Orano Med Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 Orano Med Recent Developments/Updates
10.2.6 Orano Med Competitive Strengths & Weaknesses
10.3 Oncoinvent AS
10.3.1 Oncoinvent AS Details
10.3.2 Oncoinvent AS Major Business
10.3.3 Oncoinvent AS Targeted Alpha-particle Therapy Product and Services
10.3.4 Oncoinvent AS Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Oncoinvent AS Recent Developments/Updates
10.3.6 Oncoinvent AS Competitive Strengths & Weaknesses
10.4 Perspective Therapeutics
10.4.1 Perspective Therapeutics Details
10.4.2 Perspective Therapeutics Major Business
10.4.3 Perspective Therapeutics Targeted Alpha-particle Therapy Product and Services
10.4.4 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 Perspective Therapeutics Recent Developments/Updates
10.4.6 Perspective Therapeutics Competitive Strengths & Weaknesses
10.5 Ablaze Pharma
10.5.1 Ablaze Pharma Details
10.5.2 Ablaze Pharma Major Business
10.5.3 Ablaze Pharma Targeted Alpha-particle Therapy Product and Services
10.5.4 Ablaze Pharma Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 Ablaze Pharma Recent Developments/Updates
10.5.6 Ablaze Pharma Competitive Strengths & Weaknesses
10.6 ARTBIO
10.6.1 ARTBIO Details
10.6.2 ARTBIO Major Business
10.6.3 ARTBIO Targeted Alpha-particle Therapy Product and Services
10.6.4 ARTBIO Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 ARTBIO Recent Developments/Updates
10.6.6 ARTBIO Competitive Strengths & Weaknesses
10.7 Fusion Pharmaceuticals(AstraZeneca)
10.7.1 Fusion Pharmaceuticals(AstraZeneca) Details
10.7.2 Fusion Pharmaceuticals(AstraZeneca) Major Business
10.7.3 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product and Services
10.7.4 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 Fusion Pharmaceuticals(AstraZeneca) Recent Developments/Updates
10.7.6 Fusion Pharmaceuticals(AstraZeneca) Competitive Strengths & Weaknesses
10.8 AlphaGen Therapeutics
10.8.1 AlphaGen Therapeutics Details
10.8.2 AlphaGen Therapeutics Major Business
10.8.3 AlphaGen Therapeutics Targeted Alpha-particle Therapy Product and Services
10.8.4 AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 AlphaGen Therapeutics Recent Developments/Updates
10.8.6 AlphaGen Therapeutics Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Targeted Alpha-particle Therapy Industry Chain
11.2 Targeted Alpha-particle Therapy Upstream Analysis
11.3 Targeted Alpha-particle Therapy Midstream Analysis
11.4 Targeted Alpha-particle Therapy Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Targeted Alpha-particle Therapy Introduction
1.2 World Targeted Alpha-particle Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Targeted Alpha-particle Therapy Total Market by Region (by Headquarter Location)
1.3.1 World Targeted Alpha-particle Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.3 China Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.4 Europe Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.5 Japan Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.3.8 India Based Company Targeted Alpha-particle Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Targeted Alpha-particle Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.2 World Targeted Alpha-particle Therapy Consumption Value by Region
2.2.1 World Targeted Alpha-particle Therapy Consumption Value by Region (2021-2026)
2.2.2 World Targeted Alpha-particle Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.4 China Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.5 Europe Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.6 Japan Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.7 South Korea Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.8 ASEAN Targeted Alpha-particle Therapy Consumption Value (2021-2032)
2.9 India Targeted Alpha-particle Therapy Consumption Value (2021-2032)
3 WORLD TARGETED ALPHA-PARTICLE THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Targeted Alpha-particle Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Targeted Alpha-particle Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Targeted Alpha-particle Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for Targeted Alpha-particle Therapy in 2025
3.3 Targeted Alpha-particle Therapy Company Evaluation Quadrant
3.4 Targeted Alpha-particle Therapy Market: Overall Company Footprint Analysis
3.4.1 Targeted Alpha-particle Therapy Market: Region Footprint
3.4.2 Targeted Alpha-particle Therapy Market: Company Product Type Footprint
3.4.3 Targeted Alpha-particle Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Targeted Alpha-particle Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Targeted Alpha-particle Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Targeted Alpha-particle Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Targeted Alpha-particle Therapy Consumption Value Comparison
4.2.1 United States VS China: Targeted Alpha-particle Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Targeted Alpha-particle Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Targeted Alpha-particle Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based Targeted Alpha-particle Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026)
4.4 China Based Companies Targeted Alpha-particle Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based Targeted Alpha-particle Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026)
4.5 Rest of World Based Targeted Alpha-particle Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Targeted Alpha-particle Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Targeted Alpha-particle Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Targeted Alpha-particle Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Actinium-225
5.2.2 Astatine-211
5.2.3 Lead-212
5.2.4 Bismuth-213
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Targeted Alpha-particle Therapy Market Size by Type (2021-2026)
5.3.2 World Targeted Alpha-particle Therapy Market Size by Type (2027-2032)
5.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY TARGETED CARRIERS
6.1 World Targeted Alpha-particle Therapy Market Size Overview by Targeted Carriers: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Targeted Carriers
6.2.1 Antibody-based ? Therapy
6.2.2 Peptide Receptor Radionuclide Therapy
6.2.3 Small Molecule ? Therapy
6.2.4 Nano-carrier ? Therapy
6.2.5 Cell-based ? Therapy
6.3 Market Segment by Targeted Carriers
6.3.1 World Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2021-2026)
6.3.2 World Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2027-2032)
6.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2027-2032)
7 MARKET ANALYSIS BY THERAPEUTIC TARGET
7.1 World Targeted Alpha-particle Therapy Market Size Overview by Therapeutic Target: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Therapeutic Target
7.2.1 PSMA-targeted Alpha Therapy
7.2.2 SSTR-targeted Alpha Therapy
7.2.3 CD33/CD45-targeted Alpha Therapy
7.2.4 HER2-targeted Alpha Therapy
7.2.5 EGFR-targeted Alpha Therapy
7.2.6 Others
7.3 Market Segment by Therapeutic Target
7.3.1 World Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2021-2026)
7.3.2 World Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2027-2032)
7.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2027-2032)
8 MARKET ANALYSIS BY DRUG DELIVERY METHOD
8.1 World Targeted Alpha-particle Therapy Market Size Overview by Drug Delivery Method: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Drug Delivery Method
8.2.1 Systemic Administration
8.2.2 Local Administration
8.2.3 Radioimmunotherapy
8.2.4 Combination Therapy Alpha Drugs
8.3 Market Segment by Drug Delivery Method
8.3.1 World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2021-2026)
8.3.2 World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2027-2032)
8.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Targeted Alpha-particle Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Immunotherapy
9.2.2 Peritoneal Carcinomas
9.2.3 Bone Metastases
9.2.4 Leukaemia
9.2.5 Melanomas
9.2.6 Solid Tumours
9.3 Market Segment by Application
9.3.1 World Targeted Alpha-particle Therapy Market Size by Application (2021-2026)
9.3.2 World Targeted Alpha-particle Therapy Market Size by Application (2027-2032)
9.3.3 World Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Bayer
10.1.1 Bayer Details
10.1.2 Bayer Major Business
10.1.3 Bayer Targeted Alpha-particle Therapy Product and Services
10.1.4 Bayer Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Bayer Recent Developments/Updates
10.1.6 Bayer Competitive Strengths & Weaknesses
10.2 Orano Med
10.2.1 Orano Med Details
10.2.2 Orano Med Major Business
10.2.3 Orano Med Targeted Alpha-particle Therapy Product and Services
10.2.4 Orano Med Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 Orano Med Recent Developments/Updates
10.2.6 Orano Med Competitive Strengths & Weaknesses
10.3 Oncoinvent AS
10.3.1 Oncoinvent AS Details
10.3.2 Oncoinvent AS Major Business
10.3.3 Oncoinvent AS Targeted Alpha-particle Therapy Product and Services
10.3.4 Oncoinvent AS Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Oncoinvent AS Recent Developments/Updates
10.3.6 Oncoinvent AS Competitive Strengths & Weaknesses
10.4 Perspective Therapeutics
10.4.1 Perspective Therapeutics Details
10.4.2 Perspective Therapeutics Major Business
10.4.3 Perspective Therapeutics Targeted Alpha-particle Therapy Product and Services
10.4.4 Perspective Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 Perspective Therapeutics Recent Developments/Updates
10.4.6 Perspective Therapeutics Competitive Strengths & Weaknesses
10.5 Ablaze Pharma
10.5.1 Ablaze Pharma Details
10.5.2 Ablaze Pharma Major Business
10.5.3 Ablaze Pharma Targeted Alpha-particle Therapy Product and Services
10.5.4 Ablaze Pharma Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 Ablaze Pharma Recent Developments/Updates
10.5.6 Ablaze Pharma Competitive Strengths & Weaknesses
10.6 ARTBIO
10.6.1 ARTBIO Details
10.6.2 ARTBIO Major Business
10.6.3 ARTBIO Targeted Alpha-particle Therapy Product and Services
10.6.4 ARTBIO Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 ARTBIO Recent Developments/Updates
10.6.6 ARTBIO Competitive Strengths & Weaknesses
10.7 Fusion Pharmaceuticals(AstraZeneca)
10.7.1 Fusion Pharmaceuticals(AstraZeneca) Details
10.7.2 Fusion Pharmaceuticals(AstraZeneca) Major Business
10.7.3 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product and Services
10.7.4 Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 Fusion Pharmaceuticals(AstraZeneca) Recent Developments/Updates
10.7.6 Fusion Pharmaceuticals(AstraZeneca) Competitive Strengths & Weaknesses
10.8 AlphaGen Therapeutics
10.8.1 AlphaGen Therapeutics Details
10.8.2 AlphaGen Therapeutics Major Business
10.8.3 AlphaGen Therapeutics Targeted Alpha-particle Therapy Product and Services
10.8.4 AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 AlphaGen Therapeutics Recent Developments/Updates
10.8.6 AlphaGen Therapeutics Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Targeted Alpha-particle Therapy Industry Chain
11.2 Targeted Alpha-particle Therapy Upstream Analysis
11.3 Targeted Alpha-particle Therapy Midstream Analysis
11.4 Targeted Alpha-particle Therapy Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Targeted Alpha-particle Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Targeted Alpha-particle Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Targeted Alpha-particle Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Targeted Alpha-particle Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Targeted Alpha-particle Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Targeted Alpha-particle Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Targeted Alpha-particle Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Targeted Alpha-particle Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Targeted Alpha-particle Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Targeted Alpha-particle Therapy Players in 2025
Table 12. World Targeted Alpha-particle Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Targeted Alpha-particle Therapy Company Evaluation Quadrant
Table 14. Head Office of Key Targeted Alpha-particle Therapy Players
Table 15. Targeted Alpha-particle Therapy Market: Company Product Type Footprint
Table 16. Targeted Alpha-particle Therapy Market: Company Product Application Footprint
Table 17. Targeted Alpha-particle Therapy Mergers & Acquisitions Activity
Table 18. United States VS China Targeted Alpha-particle Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Targeted Alpha-particle Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Targeted Alpha-particle Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Targeted Alpha-particle Therapy Revenue Market Share (2021-2026)
Table 23. China Based Targeted Alpha-particle Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Targeted Alpha-particle Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based Targeted Alpha-particle Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Targeted Alpha-particle Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Targeted Alpha-particle Therapy Revenue Market Share (2021-2026)
Table 29. World Targeted Alpha-particle Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Targeted Alpha-particle Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Targeted Alpha-particle Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World Targeted Alpha-particle Therapy Market Size by Targeted Carriers, (USD Million), 2021 & 2025 & 2032
Table 33. World Targeted Alpha-particle Therapy Market Size Value by Targeted Carriers (2021-2026) & (USD Million)
Table 34. World Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2027-2032) & (USD Million)
Table 35. World Targeted Alpha-particle Therapy Market Size by Therapeutic Target, (USD Million), 2021 & 2025 & 2032
Table 36. World Targeted Alpha-particle Therapy Market Size Value by Therapeutic Target (2021-2026) & (USD Million)
Table 37. World Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2027-2032) & (USD Million)
Table 38. World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method, (USD Million), 2021 & 2025 & 2032
Table 39. World Targeted Alpha-particle Therapy Market Size Value by Drug Delivery Method (2021-2026) & (USD Million)
Table 40. World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2027-2032) & (USD Million)
Table 41. World Targeted Alpha-particle Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & (USD Million)
Table 43. World Targeted Alpha-particle Therapy Market Size by Application (2027-2032) & (USD Million)
Table 44. Bayer Basic Information, Manufacturing Base and Competitors
Table 45. Bayer Major Business
Table 46. Bayer Targeted Alpha-particle Therapy Product and Services
Table 47. Bayer Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Bayer Recent Developments/Updates
Table 49. Bayer Competitive Strengths & Weaknesses
Table 50. Orano Med Basic Information, Manufacturing Base and Competitors
Table 51. Orano Med Major Business
Table 52. Orano Med Targeted Alpha-particle Therapy Product and Services
Table 53. Orano Med Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Orano Med Recent Developments/Updates
Table 55. Orano Med Competitive Strengths & Weaknesses
Table 56. Oncoinvent AS Basic Information, Manufacturing Base and Competitors
Table 57. Oncoinvent AS Major Business
Table 58. Oncoinvent AS Targeted Alpha-particle Therapy Product and Services
Table 59. Oncoinvent AS Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Oncoinvent AS Recent Developments/Updates
Table 61. Oncoinvent AS Competitive Strengths & Weaknesses
Table 62. Perspective Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. Perspective Therapeutics Major Business
Table 64. Perspective Therapeutics Targeted Alpha-particle Therapy Product and Services
Table 65. Perspective Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Perspective Therapeutics Recent Developments/Updates
Table 67. Perspective Therapeutics Competitive Strengths & Weaknesses
Table 68. Ablaze Pharma Basic Information, Manufacturing Base and Competitors
Table 69. Ablaze Pharma Major Business
Table 70. Ablaze Pharma Targeted Alpha-particle Therapy Product and Services
Table 71. Ablaze Pharma Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Ablaze Pharma Recent Developments/Updates
Table 73. Ablaze Pharma Competitive Strengths & Weaknesses
Table 74. ARTBIO Basic Information, Manufacturing Base and Competitors
Table 75. ARTBIO Major Business
Table 76. ARTBIO Targeted Alpha-particle Therapy Product and Services
Table 77. ARTBIO Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. ARTBIO Recent Developments/Updates
Table 79. ARTBIO Competitive Strengths & Weaknesses
Table 80. Fusion Pharmaceuticals(AstraZeneca) Basic Information, Manufacturing Base and Competitors
Table 81. Fusion Pharmaceuticals(AstraZeneca) Major Business
Table 82. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product and Services
Table 83. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Fusion Pharmaceuticals(AstraZeneca) Recent Developments/Updates
Table 85. Fusion Pharmaceuticals(AstraZeneca) Competitive Strengths & Weaknesses
Table 86. AlphaGen Therapeutics Basic Information, Manufacturing Base and Competitors
Table 87. AlphaGen Therapeutics Major Business
Table 88. AlphaGen Therapeutics Targeted Alpha-particle Therapy Product and Services
Table 89. AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. AlphaGen Therapeutics Recent Developments/Updates
Table 91. AlphaGen Therapeutics Competitive Strengths & Weaknesses
Table 92. Global Key Players of Targeted Alpha-particle Therapy Upstream (Raw Materials)
Table 93. Global Targeted Alpha-particle Therapy Typical Customers
Table 1. World Targeted Alpha-particle Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Targeted Alpha-particle Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Targeted Alpha-particle Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Targeted Alpha-particle Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Targeted Alpha-particle Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Targeted Alpha-particle Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Targeted Alpha-particle Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Targeted Alpha-particle Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Targeted Alpha-particle Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Targeted Alpha-particle Therapy Players in 2025
Table 12. World Targeted Alpha-particle Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Targeted Alpha-particle Therapy Company Evaluation Quadrant
Table 14. Head Office of Key Targeted Alpha-particle Therapy Players
Table 15. Targeted Alpha-particle Therapy Market: Company Product Type Footprint
Table 16. Targeted Alpha-particle Therapy Market: Company Product Application Footprint
Table 17. Targeted Alpha-particle Therapy Mergers & Acquisitions Activity
Table 18. United States VS China Targeted Alpha-particle Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Targeted Alpha-particle Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Targeted Alpha-particle Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Targeted Alpha-particle Therapy Revenue Market Share (2021-2026)
Table 23. China Based Targeted Alpha-particle Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Targeted Alpha-particle Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Targeted Alpha-particle Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based Targeted Alpha-particle Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Targeted Alpha-particle Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Targeted Alpha-particle Therapy Revenue Market Share (2021-2026)
Table 29. World Targeted Alpha-particle Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Targeted Alpha-particle Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Targeted Alpha-particle Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World Targeted Alpha-particle Therapy Market Size by Targeted Carriers, (USD Million), 2021 & 2025 & 2032
Table 33. World Targeted Alpha-particle Therapy Market Size Value by Targeted Carriers (2021-2026) & (USD Million)
Table 34. World Targeted Alpha-particle Therapy Market Size by Targeted Carriers (2027-2032) & (USD Million)
Table 35. World Targeted Alpha-particle Therapy Market Size by Therapeutic Target, (USD Million), 2021 & 2025 & 2032
Table 36. World Targeted Alpha-particle Therapy Market Size Value by Therapeutic Target (2021-2026) & (USD Million)
Table 37. World Targeted Alpha-particle Therapy Market Size by Therapeutic Target (2027-2032) & (USD Million)
Table 38. World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method, (USD Million), 2021 & 2025 & 2032
Table 39. World Targeted Alpha-particle Therapy Market Size Value by Drug Delivery Method (2021-2026) & (USD Million)
Table 40. World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method (2027-2032) & (USD Million)
Table 41. World Targeted Alpha-particle Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World Targeted Alpha-particle Therapy Market Size by Application (2021-2026) & (USD Million)
Table 43. World Targeted Alpha-particle Therapy Market Size by Application (2027-2032) & (USD Million)
Table 44. Bayer Basic Information, Manufacturing Base and Competitors
Table 45. Bayer Major Business
Table 46. Bayer Targeted Alpha-particle Therapy Product and Services
Table 47. Bayer Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Bayer Recent Developments/Updates
Table 49. Bayer Competitive Strengths & Weaknesses
Table 50. Orano Med Basic Information, Manufacturing Base and Competitors
Table 51. Orano Med Major Business
Table 52. Orano Med Targeted Alpha-particle Therapy Product and Services
Table 53. Orano Med Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Orano Med Recent Developments/Updates
Table 55. Orano Med Competitive Strengths & Weaknesses
Table 56. Oncoinvent AS Basic Information, Manufacturing Base and Competitors
Table 57. Oncoinvent AS Major Business
Table 58. Oncoinvent AS Targeted Alpha-particle Therapy Product and Services
Table 59. Oncoinvent AS Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Oncoinvent AS Recent Developments/Updates
Table 61. Oncoinvent AS Competitive Strengths & Weaknesses
Table 62. Perspective Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. Perspective Therapeutics Major Business
Table 64. Perspective Therapeutics Targeted Alpha-particle Therapy Product and Services
Table 65. Perspective Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Perspective Therapeutics Recent Developments/Updates
Table 67. Perspective Therapeutics Competitive Strengths & Weaknesses
Table 68. Ablaze Pharma Basic Information, Manufacturing Base and Competitors
Table 69. Ablaze Pharma Major Business
Table 70. Ablaze Pharma Targeted Alpha-particle Therapy Product and Services
Table 71. Ablaze Pharma Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Ablaze Pharma Recent Developments/Updates
Table 73. Ablaze Pharma Competitive Strengths & Weaknesses
Table 74. ARTBIO Basic Information, Manufacturing Base and Competitors
Table 75. ARTBIO Major Business
Table 76. ARTBIO Targeted Alpha-particle Therapy Product and Services
Table 77. ARTBIO Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. ARTBIO Recent Developments/Updates
Table 79. ARTBIO Competitive Strengths & Weaknesses
Table 80. Fusion Pharmaceuticals(AstraZeneca) Basic Information, Manufacturing Base and Competitors
Table 81. Fusion Pharmaceuticals(AstraZeneca) Major Business
Table 82. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Product and Services
Table 83. Fusion Pharmaceuticals(AstraZeneca) Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Fusion Pharmaceuticals(AstraZeneca) Recent Developments/Updates
Table 85. Fusion Pharmaceuticals(AstraZeneca) Competitive Strengths & Weaknesses
Table 86. AlphaGen Therapeutics Basic Information, Manufacturing Base and Competitors
Table 87. AlphaGen Therapeutics Major Business
Table 88. AlphaGen Therapeutics Targeted Alpha-particle Therapy Product and Services
Table 89. AlphaGen Therapeutics Targeted Alpha-particle Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. AlphaGen Therapeutics Recent Developments/Updates
Table 91. AlphaGen Therapeutics Competitive Strengths & Weaknesses
Table 92. Global Key Players of Targeted Alpha-particle Therapy Upstream (Raw Materials)
Table 93. Global Targeted Alpha-particle Therapy Typical Customers
LIST OF FIGURES
Figure 1. Targeted Alpha-particle Therapy Picture
Figure 2. World Targeted Alpha-particle Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Targeted Alpha-particle Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World Targeted Alpha-particle Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Targeted Alpha-particle Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 13. Targeted Alpha-particle Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World Targeted Alpha-particle Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Targeted Alpha-particle Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted Alpha-particle Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted Alpha-particle Therapy Markets in 2025
Figure 27. United States VS China: Targeted Alpha-particle Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Targeted Alpha-particle Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Targeted Alpha-particle Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Targeted Alpha-particle Therapy Market Size Market Share by Type in 2025
Figure 31. Actinium-225
Figure 32. Astatine-211
Figure 33. Lead-212
Figure 34. Bismuth-213
Figure 35. Others
Figure 36. World Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2032)
Figure 37. World Targeted Alpha-particle Therapy Market Size by Targeted Carriers, (USD Million), 2021 & 2025 & 2032
Figure 38. World Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers in 2025
Figure 39. Antibody-based ? Therapy
Figure 40. Peptide Receptor Radionuclide Therapy
Figure 41. Small Molecule ? Therapy
Figure 42. Nano-carrier ? Therapy
Figure 43. Cell-based ? Therapy
Figure 44. World Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2021-2032)
Figure 45. World Targeted Alpha-particle Therapy Market Size by Therapeutic Target, (USD Million), 2021 & 2025 & 2032
Figure 46. World Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target in 2025
Figure 47. PSMA-targeted Alpha Therapy
Figure 48. SSTR-targeted Alpha Therapy
Figure 49. CD33/CD45-targeted Alpha Therapy
Figure 50. HER2-targeted Alpha Therapy
Figure 51. EGFR-targeted Alpha Therapy
Figure 52. Others
Figure 53. World Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2021-2032)
Figure 54. World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method, (USD Million), 2021 & 2025 & 2032
Figure 55. World Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method in 2025
Figure 56. Systemic Administration
Figure 57. Local Administration
Figure 58. Radioimmunotherapy
Figure 59. Combination Therapy Alpha Drugs
Figure 60. World Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2021-2032)
Figure 61. World Targeted Alpha-particle Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 62. World Targeted Alpha-particle Therapy Market Size Market Share by Application in 2025
Figure 63. Immunotherapy
Figure 64. Peritoneal Carcinomas
Figure 65. Bone Metastases
Figure 66. Leukaemia
Figure 67. Melanomas
Figure 68. Solid Tumours
Figure 69. World Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2032)
Figure 70. Targeted Alpha-particle Therapy Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Figure 1. Targeted Alpha-particle Therapy Picture
Figure 2. World Targeted Alpha-particle Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Targeted Alpha-particle Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World Targeted Alpha-particle Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Targeted Alpha-particle Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Targeted Alpha-particle Therapy Revenue (2021-2032) & (USD Million)
Figure 13. Targeted Alpha-particle Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World Targeted Alpha-particle Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India Targeted Alpha-particle Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Targeted Alpha-particle Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Targeted Alpha-particle Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Targeted Alpha-particle Therapy Markets in 2025
Figure 27. United States VS China: Targeted Alpha-particle Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Targeted Alpha-particle Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Targeted Alpha-particle Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Targeted Alpha-particle Therapy Market Size Market Share by Type in 2025
Figure 31. Actinium-225
Figure 32. Astatine-211
Figure 33. Lead-212
Figure 34. Bismuth-213
Figure 35. Others
Figure 36. World Targeted Alpha-particle Therapy Market Size Market Share by Type (2021-2032)
Figure 37. World Targeted Alpha-particle Therapy Market Size by Targeted Carriers, (USD Million), 2021 & 2025 & 2032
Figure 38. World Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers in 2025
Figure 39. Antibody-based ? Therapy
Figure 40. Peptide Receptor Radionuclide Therapy
Figure 41. Small Molecule ? Therapy
Figure 42. Nano-carrier ? Therapy
Figure 43. Cell-based ? Therapy
Figure 44. World Targeted Alpha-particle Therapy Market Size Market Share by Targeted Carriers (2021-2032)
Figure 45. World Targeted Alpha-particle Therapy Market Size by Therapeutic Target, (USD Million), 2021 & 2025 & 2032
Figure 46. World Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target in 2025
Figure 47. PSMA-targeted Alpha Therapy
Figure 48. SSTR-targeted Alpha Therapy
Figure 49. CD33/CD45-targeted Alpha Therapy
Figure 50. HER2-targeted Alpha Therapy
Figure 51. EGFR-targeted Alpha Therapy
Figure 52. Others
Figure 53. World Targeted Alpha-particle Therapy Market Size Market Share by Therapeutic Target (2021-2032)
Figure 54. World Targeted Alpha-particle Therapy Market Size by Drug Delivery Method, (USD Million), 2021 & 2025 & 2032
Figure 55. World Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method in 2025
Figure 56. Systemic Administration
Figure 57. Local Administration
Figure 58. Radioimmunotherapy
Figure 59. Combination Therapy Alpha Drugs
Figure 60. World Targeted Alpha-particle Therapy Market Size Market Share by Drug Delivery Method (2021-2032)
Figure 61. World Targeted Alpha-particle Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 62. World Targeted Alpha-particle Therapy Market Size Market Share by Application in 2025
Figure 63. Immunotherapy
Figure 64. Peritoneal Carcinomas
Figure 65. Bone Metastases
Figure 66. Leukaemia
Figure 67. Melanomas
Figure 68. Solid Tumours
Figure 69. World Targeted Alpha-particle Therapy Market Size Market Share by Application (2021-2032)
Figure 70. Targeted Alpha-particle Therapy Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
